The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study
Abstract Background For high-risk stageIImismatch repair deficient (dMMR) colon cancers, the benefit of adjuvant chemotherapy remains debatable. The principal aim of this study was to evaluate the prognostic value of high-risk factors and the effect of oxaliplatin-based adjuvant chemotherapy among d...
Main Authors: | Leen Liao, Jinghua Tang, Zhigang Hong, Wu Jiang, Yuan Li, Lingheng Kong, Kai Han, Zhenlin Hou, Chenzhi Zhang, Chi Zhou, Linjie Zhang, Qiaoqi Sui, Binyi Xiao, Weijian Mei, Jiehai Yu, Wanjun Yang, Zhizhong Pan, Pei-Rong Ding |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-02-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-024-11821-w |
Similar Items
-
Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
by: Huabin Hu, et al.
Published: (2020-12-01) -
Effects of deficient mismatch repair on the prognosis of patients with stage II and stage III colon cancer during different postoperative periods
by: Chunze Zhang, et al.
Published: (2022-11-01) -
Clinical implication of adjuvant chemotherapy according to mismatch repair status in patients with intermediate-risk stage II colon cancer: a retrospective study
by: Byung Woog Kang, et al.
Published: (2022-04-01) -
Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis
by: Diana Groza, et al.
Published: (2018-05-01) -
Lymphovascular invasion represents a superior prognostic and predictive pathological factor of the duration of adjuvant chemotherapy for stage III colon cancer patients
by: Linjie Zhang, et al.
Published: (2023-01-01)